1. P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn's disease by baseline disease severity. (30th January 2023) Authors: Siegmund, B; Patel, K; Torres, E A; Lakatos, P L; Seidelin, J; Fleisher, M; Ford, S; Remple, V; Lacerda, A P; Anyanwu, S; Garrison, A; Panés, J Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i636 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn's disease treated with upadacitinib. (30th January 2023) Authors: Dubinsky, M C; D'Haens, G; Dewit, O; Juillerat, P; Panaccione, R; Fujii, T; Lacerda, A P; Dubcenco, E; Anyanwu, S; Doshi, C; Mallick, M; Garrison, A; Liu, J; Loftus Jr, E V Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP38 Upadacitinib Therapy Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy. (30th January 2023) Authors: Colombel, J F; Hisamatsu, T; Bresso, F; Thin, L; Parra, R; Ford, S; Remple, V; Lacerda, A P; Hecht, P; Mallick, M; Garrison, A; Regueiro, M Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn's disease by number and type of prior biologics. (30th January 2023) Authors: Peyrin-Biroulet, L; Parkes, G; Rodríguez, C; Siffledeen, J; Wright, J; Broide, E; Ford, S; Lacerda, A P; Oomen, J; Garrison, A; Berg, S; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn's disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies. (30th January 2023) Authors: Vermeire, S; Danese, S; Cohen, B L; Magro, F; Chen, Y; Ha, C; Dubcenco, E; Lacerda, A P; Marced, E; Oomen, J; Garrison, A; Peyrin-Biroulet, L Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗